Laboratory diagnosis of toxoplasmosis in immunocompromised patients HIV-infected patients, haematopoietic stem cell transplant recipients and solid organ transplant recipients - INAHTA Brief

-
Health technology assessment - Posted on May 29 2017

This assessment corresponds to the second part of a response to a request from the Caisse nationale d’assurance maladie des travailleurs salariés (CNAMTS - National Health Insurance fund for salaried workers), which wishes to update the Nomenclature des actes de biologie médicale (NABM - Nomenclature of Procedures in Laboratory Medicine) in relation to procedures for the laboratory diagnosis of toxoplasmosis. This parasitic disease, caused by the protozoan Toxoplasma gondii, groups together some very distinct clinical and biological contexts. A first part of the assessment, validated in February 2017, concerned the laboratory diagnosis of acquired toxoplasmosis in immunocompetent subjects (including pregnant women), congenital toxoplasmosis and ocular toxoplasmosis. This second part focuses on diagnostic tests for toxoplasmosis in immunocompromised patients, in particular patients infected with human immunodeficiency virus (HIV), and haematopoietic stem cell transplant (HSCT) or solid organ transplant recipients.

Contact Us

Évaluation des actes professionnels